Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, placebo-controlled, double-blind, parallel-group, multicentre, phase IIa study to explore the relationship between QTcF interval at first dose (loading dose) and at steady state after treatment with AZD1305 extended-release tablets or placebo when given to patients with documented atrial fibrillation.

Next Previous
Search
Trial Profile

A randomised, placebo-controlled, double-blind, parallel-group, multicentre, phase IIa study to explore the relationship between QTcF interval at first dose (loading dose) and at steady state after treatment with AZD1305 extended-release tablets or placebo when given to patients with documented atrial fibrillation.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 1305 (Primary)
  • Indications Atrial fibrillation
  • Focus Pharmacogenomic; Therapeutic Use

    • Most Recent Events

    • 25 Jan 2012 Actual patient number (65) added as reported by ClinicalTrials.gov.
    • 16 Nov 2011 Actual trial initiation date changed from 1 Mar 2008 to 21 Feb 2008.
    • 01 Jun 2011 Results published in the American Journal of Cardiovascular Drugs.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top